Skip to NavigationSkip to content

GSK's Nucala meets Phase 3 goal in reducing hypereosinophilic syndrome flare-ups

Published on 13/11/19 at 11:41am

GlaxoSmithKline has unveiled new Phase 3 data for its IL-5 inhibitor Nucala (mepolizumab), revealing that the therapy met its primary endpoint in the treatment of the rare disease hypereosinophilic syndrome (HES).

In the trial, 50% fewer participants were shown to experience a flare-up of HES-related symptoms when treated with Nucala alongside standard of care as opposed to placebo plus standard of care over 32 weeks of treatment.

Additionally, Nucala patients exhibited a 66% lower risk of first HES flare-up compared to placebo, as well as a 66% reduction in the annualised rate of flare-ups.  On the back of the trial results, GSK asserted that Nucala was the first therapy to demonstrably reduce HES-related flare-ups. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, remarked: “Mepolizumab has the potential to change the treatment landscape for patients with HES which is a complex and debilitating disease with limited therapeutic options today.”

Dr Gerald Gleich, an allergist, immunologist and HES expert at the University of Utah, also commented: “Mepolizumab is thought to work by reducing blood eosinophil levels and evidence suggests it has potential as a targeted treatment option for a range of inflammatory diseases driven by raised eosinophils. These data are very promising and should provide hope for patients affected by this rare, life-threatening condition caused by eosinophilic inflammation.”

GSK confirmed it would be submitting these data to regulatory bodies around the world in a bit to secure the first HES-related approvals for Nucala.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches